Literature DB >> 25701273

Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trial.

Jolyn Hersch1, Alexandra Barratt2, Jesse Jansen1, Les Irwig3, Kevin McGeechan2, Gemma Jacklyn4, Hazel Thornton5, Haryana Dhillon6, Nehmat Houssami3, Kirsten McCaffery7.   

Abstract

BACKGROUND: Mammography screening can reduce breast cancer mortality. However, most women are unaware that inconsequential disease can also be detected by screening, leading to overdiagnosis and overtreatment. We aimed to investigate whether including information about overdetection of breast cancer in a decision aid would help women aged around 50 years to make an informed choice about breast screening.
METHODS: We did a community-based, parallel-group, randomised controlled trial in New South Wales, Australia, using a random cohort of women aged 48-50 years. Recruitment to the study was done by telephone; women were eligible if they had not had mammography in the past 2 years and did not have a personal or strong family history of breast cancer. With a computer program, we randomly assigned 879 participants to either the intervention decision aid (comprising evidence-based explanatory and quantitative information on overdetection, breast cancer mortality reduction, and false positives) or a control decision aid (including information on breast cancer mortality reduction and false positives). Participants and interviewers were masked to group assignment. The primary outcome was informed choice (defined as adequate knowledge and consistency between attitudes and screening intentions), which we assessed by telephone interview about 3 weeks after random allocation. The primary outcome was analysed in all women who completed the relevant follow-up interview questions fully. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12613001035718.
FINDINGS: Between January, 2014, and July, 2014, 440 women were allocated to the intervention group and 439 were assigned to the control group. 21 women in the intervention group and 20 controls were lost to follow-up; a further ten women assigned to the intervention and 11 controls did not answer all questions on attitudes. Therefore, 409 women in the intervention group and 408 controls were analysed for the primary outcome. 99 (24%) of 409 women in the intervention group made an informed choice compared with 63 (15%) of 408 in the control group (difference 9%, 95% CI 3-14; p=0·0017). Compared with controls, more women in the intervention group met the threshold for adequate overall knowledge (122/419 [29%] vs 71/419 [17%]; difference 12%, 95% CI 6-18; p<0·0001), fewer women expressed positive attitudes towards screening (282/409 [69%] vs 340/408 [83%]; 14%, 9-20; p<0·0001), and fewer women intended to be screened (308/419 [74%] vs 363/419 [87%]; 13%, 8-19; p<0·0001). When conceptual knowledge alone was considered, 203 (50%) of 409 women in the intervention group made an informed choice compared with 79 (19%) of 408 in the control group (p<0·0001).
INTERPRETATION: Information on overdetection of breast cancer provided within a decision aid increased the number of women making an informed choice about breast screening. Becoming better informed might mean women are less likely to choose screening. FUNDING: Australian National Health and Medical Research Council.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25701273     DOI: 10.1016/S0140-6736(15)60123-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  89 in total

1.  Perspective: The risks of overdiagnosis.

Authors:  Alexandra Barratt
Journal:  Nature       Date:  2015-11-19       Impact factor: 49.962

2.  The mammography debate, round two: science, smoke and mirrors.

Authors:  C Kaniklidis
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

3.  Usability Testing of a Web-Based Decision Aid for Breast Cancer Risk Assessment Among Multi-Ethnic Women.

Authors:  Austin M Coe; William Ueng; Jennifer M Vargas; Raven David; Alejandro Vanegas; Katherine Infante; Meghna Trivedi; Haeseung Yi; Jill Dimond; Katherine D Crew; Rita Kukafka
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10

4.  Fragility, uncertainty, and healthcare.

Authors:  Wendy A Rogers; Mary J Walker
Journal:  Theor Med Bioeth       Date:  2016-02

5.  Risk, Overdiagnosis and Ethical Justifications.

Authors:  Wendy A Rogers; Vikki A Entwistle; Stacy M Carter
Journal:  Health Care Anal       Date:  2019-12

6.  Recommendations on screening for breast cancer in women aged 40-74 years who are not at increased risk for breast cancer.

Authors:  Scott Klarenbach; Nicki Sims-Jones; Gabriela Lewin; Harminder Singh; Guylène Thériault; Marcello Tonelli; Marion Doull; Susan Courage; Alejandra Jaramillo Garcia; Brett D Thombs
Journal:  CMAJ       Date:  2018-12-10       Impact factor: 8.262

7.  Overdiagnosis: one concept, three perspectives, and a model.

Authors:  Bjørn Hofmann; Lynette Reid; Stacy Carter; Wendy Rogers
Journal:  Eur J Epidemiol       Date:  2021-01-11       Impact factor: 8.082

8.  The overdiagnosis of what? On the relationship between the concepts of overdiagnosis, disease, and diagnosis.

Authors:  Bjørn Hofmann
Journal:  Med Health Care Philos       Date:  2017-12

9.  Association of Preferences for Papillary Thyroid Cancer Treatment With Disease Terminology: A Discrete Choice Experiment.

Authors:  Brooke Nickel; Kirsten Howard; Juan P Brito; Alexandra Barratt; Ray Moynihan; Kirsten McCaffery
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-10-01       Impact factor: 6.223

10.  Non-maleficence and the ethics of consent to cancer screening.

Authors:  Lotte Elton
Journal:  J Med Ethics       Date:  2020-09-21       Impact factor: 2.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.